Unknown

Dataset Information

Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial.


ABSTRACT:

Background/aims

To evaluate the cost-effectiveness of ranibizumab as either monotherapy or combined with laser therapy, compared with laser monotherapy, in the treatment of diabetic macular oedema (DME) causing visual impairment from a UK healthcare payer perspective.

Methods

A Markov model simulated long-term outcomes and costs of treating DME in one eye (BCVA ≤75 letters) based on data from the RESTORE Phase III trial. Outcomes measured in quality-adjusted life-years (QALYs) were simulated for a 15-year time horizon based on 12-month follow-up from RESTORE and published long-term data. Costs included treatment, disease monitoring, visual impairment and blindness (at 2010 price levels).

Results

Ranibizumab monotherapy resulted in a 0.17 QALY gain at an incremental co

SUBMITTER: Mitchell P 

PROVIDER: S-EPMC3329632 | biostudies-literature | 2012 May

REPOSITORIES: biostudies-literature